RET and medullary thyroid gland carcinoma: While RET-specific inhibitors do not seem to be significantly affected by the RET V804 variant in vitro, the RET G810 variant appears to markedly reduce Selpercatinib sensitivity and impair Pralsetinib action in RET M918T-positive MTC cell lines [185].